The U.S. Department of Health and Human Services' (HHS) proposed rule to remove the anti-kickback safe harbor for prescription drug rebates paid to pharmacy benefit managers (PBMs) likely will not result in lower list prices, according to a new Congressional Budget Office (CBO) projection.